Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study

Medizinische Klinik und Poliklinik II, Universitätsklinik Würzburg, Würzburg
Department of Hematology, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron University Hospital, Barcelona
Centre Hospitalier Universitaire CHU UCL Namur, Belgium
Division of Hematology, Department of Translational Medicine University of Eastern Piedmont and Ospedale Maggiore della Carità, Novara
Department of Hematology, Institut Català d'Oncologia, Hospitalet de Llobregat, IDIBELL, Univeristat de Barcelona, Barcelona
Department of Clinical Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Kraków
Department of Molecular and Clinical Cancer University of Liverpool, Liverpool, United Kingdom
Università degli Studi di Perugia, Azienda Ospedaliera Santa Maria di Terni, Terni
Department of Internal Medicine, Arthur G James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH
Freeman Hospital, The Newcastle upon Tyne Hospitals, Newcastle upon Tyne, United Kingdom
Semmelweis University, Budapest, Hungary
CHU de Clermont-Ferrand, Lyon
MorphoSys AG, Planegg
MorphoSys AG, Planegg
MorphoSys AG, Planegg
MorphoSys AG, Planegg
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Vol. 109 No. 2 (2024): February, 2024